Confidence In SpringWorks Grows With Expanded GSK Deal And Nirogacestat Plans
On Track For First Approval In 2023
Executive Summary
SpringWorks is on course to bring nirogacestat to market by next year – and could play a pivotal role in making BCMA-targeting drugs a success.